SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solidion Technology, Inc. engages in researching, developing and manufacturing battery components and materials, batteries and related energy storage products for the automotive electric vehicle and other markets. The company was founded on June 30, 2023 and is headquartered in Dallas, TX.

Solidion Technology Inc

Solidion Technology is experiencing significant market attention and volatility driven by its recent patent disclosures and strategic pivot into the space and AI-energy infrastructure sectors, particularly as investors speculate on potential synergies with SpaceX. While the community is actively debating the stock's massive short interest and the potential for a short squeeze, many are focused on whether the company will manage its capital effectively or initiate further equity offerings.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure is trending as investors weigh an upsized 400 million convertible note offering against high expectations for imminent hyperscaler data center contracts. While some community members worry about the optics of raising capital, many bulls view the move as a bullish signal that the company is aggressively funding expansion to meet massive AI energy demand.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is experiencing heightened volatility driven by geopolitical escalation in the Middle East and concerns over a potential burst in the AI-driven tech bubble. Community sentiment is deeply divided, with traders closely monitoring the impact of foreign market instability, oil price fluctuations, and high-stakes government diplomacy on market direction.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant momentum as investors increasingly recognize the critical role of its QNX operating system in powering the expanding Physical AI and robotics sectors. The community is actively discussing the stock's transition from a legacy name to a vital infrastructure player in autonomous systems, often highlighting long-term conviction in the company's foundational safety and security technology.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Market participants are weighing the implications of heightened geopolitical tensions in the Middle East alongside the looming SpaceX IPO, creating significant uncertainty and volatility across tech-heavy indices. The community is actively debating whether recent pullbacks represent a healthy buying opportunity driven by AI infrastructure spending or the early stages of a broader bubble correction.

Roundhill ETF Trust - Roundhill Memory ETF

The Roundhill Memory ETF is trending as investors aggressively build positions in the memory supply chain, fueled by record-breaking valuation milestones for key components like SK Hynix and Micron. Community discussion is dominated by the belief that a structural, long-term shortage of HBM and DRAM will continue to drive demand, leading many to use this ETF as a consolidated play to gain exposure to the critical infrastructure backing AI compute.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors react to a significant earnings beat and a new multibillion-dollar share buyback authorization, with many in the community debating whether these developments provide enough momentum to trigger a short squeeze. Meanwhile, ongoing discussions focus on Ryan Cohen's strategic accumulation of eBay shares and widespread frustration regarding alleged market manipulation and synthetic share suppression.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors digest the company's aggressive acquisition strategy, including a series of deals to bolster its infectious disease vaccine portfolio, alongside strong sentiment regarding the clinical success and growth trajectory of its GLP-1 weight-loss franchise. Community sentiment remains largely bullish, focusing on the company's ability to maintain a competitive lead through pipeline depth and strategic partnerships despite ongoing sector-wide price pressures and market rotation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing a significant sell-off as investors pull back from high-flying AI and semiconductor stocks amid concerns over rising Treasury yields, hot jobs data, and broader macroeconomic uncertainty. The community is actively debating whether this is a healthy consolidation within a long-term bull market or the long-anticipated popping of an AI-driven bubble.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs (PL) shares are experiencing heightened volatility and intense community discussion following a strategic $1.5 billion 'at-the-market' offering, which investors are weighing against strong recent earnings and rising institutional price targets. The stock remains a focal point for traders navigating the broader space sector, as community sentiment is deeply divided between those viewing the pullback as a generational buying opportunity and others concerned about near-term dilution pressure ahead of the upcoming SpaceX IPO.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IOVA I am sure many are curious about the lung cancer situation. I will share this from my Chat. I will need multiple posts to cover 
 
Can you give me deep dive on nsclc information shaping up for iova.  
 
I’ll treat this as an investor-focused clinical/regulatory deep dive: current NSCLC data, why it matters scientifically, likely development path, and what could make it valuable or disappointing. 
 
Yes. NSCLC is shaping up as the real “company-maker” indication for IOVA, much bigger than melanoma, but still with real execution/regulatory risk. 
 
Core data: Iovance reported interim IOV-LUN-202 data in previously treated advanced nonsquamous NSCLC: 25.6% ORR, 71.8% disease-control rate, 10 responses out of 39, including 2 complete responses, and median duration of response not reached after 25.4 months. That durability is the key, not just the response rate.

Aurinia Beach

The Icc

Alex

Anthony Westfall

Rober

Ronald

Kevin Sommer

Daniel Bender

Danny Rizzi

Pedro C

$IOVA According to the recent conference, the CEO stated that the lung cancer trial only requires 80 patients. Currently, with 39 patients data, the response rate is 26%. If none of the next 40 patients respond to the treatment, would the response rate still be comparable to the current second-line treatment?  The FDA should have approved based on the current data already.

StockTwits For Android 

StockTwits Web

Iovance Biotherapeutics Inc

 I am sure many are curious about the lung cancer situation. I will share this from my Chat. I will need multiple posts to cover 
 
Can you give me deep dive on nsclc information shaping up for iova.  
 
I’ll treat this as an investor-focused clinical/regulatory deep dive: current NSCLC data, why it matters scientifically, likely development path, and what could make it valuable or disappointing. 
 
Yes. NSCLC is shaping up as the real “company-maker” indication for IOVA, much bigger than melanoma, but still with real execution/regulatory risk. 
 
Core data: Iovance reported interim IOV-LUN-202 data in previously treated advanced nonsquamous NSCLC: 25.6% ORR, 71.8% disease-control rate, 10 responses out of 39, including 2 complete responses, and median duration of response not reached after 25.4 months. That durability is the key, not just the response rate.

John

Why this matters: after checkpoint inhibitor + chemo, standard options are weak. Iovance compares against docetaxel monotherapy showing 12.8% ORR, 5.6-month median DOR, and 12.3-month OS, with no complete responses. So lifileucel is not just “a little better” on response; it may be qualitatively different if those durable responses hold. The trial is registrational Phase 2, in metastatic/unresectable NSCLC without EGFR, ROS1, or ALK actionable mutations, after prior checkpoint inhibitor and chemotherapy. Iovance says enrollment should complete in 2H 2026, additional data will be presented in 2026, and it expects to move toward an sBLA with possible launch in 2H 2027. The bull case: NSCLC is enormous. Lung cancer has about 226,000 new U.S. cases/year, about 85% NSCLC, and nonsquamous is roughly 75% of NSCLC. Even after excluding driver-mutated patients and narrowing to post-chemo/immunotherapy, this is still a far larger market than post-PD-1 melanoma.

Ed B

FL Man

Bernard O'Neill

The risk: safety and logistics. The trial had a prior clinical hold after a patient death potentially related to lymphodepletion, though FDA later lifted the hold. Recent data say the updated reduced lymphodepletion regimen cut median post-IL-2 hospitalization days by more than half and improved cytopenia recovery without hurting efficacy. That is very important commercially because lung cancer patients are often older, frailer, and sicker than melanoma patients. My take: this is the best non-melanoma signal Iovance has. A 25–26% ORR in this setting is good. But complete responses plus unreached DOR after ~25 months is what could make oncologists and regulators pay attention. The key question is whether the 39-patient signal holds as the dataset expands toward ~120–170 patients. If final ORR stays around 22–28% with long DOR and manageable safety, NSCLC could dwarf Amtagvi melanoma. If ORR falls into the teens or safety/logistics remain burdensome, the market will discount it heavily.

Give me a concise no BS summary for Stocktwits. No hopium. Pure data 
 
Here&#39;s a StockTwits-style version with no hype: 
 
$IOVA NSCLC remains the most important value driver beyond melanoma. Current IOV-LUN-202 data: 25.6% ORR (10/39), 2 complete responses, 71.8% disease control rate, and median duration of response not reached after 25.4 months follow-up. Enrollment completion expected 2H26, potential sBLA filing path in 2026, possible launch 2H27. Key question isn&#39;t ORR—it&#39;s whether durability holds as patient numbers increase. If final data stays near 25% ORR with long-lasting responses, NSCLC could be materially larger than melanoma. If efficacy regresses into the teens, the thesis weakens substantially. Data so far are encouraging but still based on a relatively small patient population.

Give me a concise no BS summary for Stocktwits. No hopium. Pure data 
 
Here's a StockTwits-style version with no hype: 
 


 NSCLC remains the most important value driver beyond melanoma. Current IOV-LUN-202 data: 25.6% ORR (10/39), 2 complete responses, 71.8% disease control rate, and median duration of response not reached after 25.4 months follow-up. Enrollment completion expected 2H26, potential sBLA filing path in 2026, possible launch 2H27. Key question isn't ORR—it's whether durability holds as patient numbers increase. If final data stays near 25% ORR with long-lasting responses, NSCLC could be materially larger than melanoma. If efficacy regresses into the teens, the thesis weakens substantially. Data so far are encouraging but still based on a relatively small patient population.

Even shorter: 
 
$IOVA NSCLC update: 25.6% ORR, 2 CRs, 71.8% DCR, median DOR not reached at 25.4 months. Promising signal in a difficult post-checkpoint/post-chemo setting, but still only 39 patients. Biggest risk is whether these results hold as enrollment expands. Biggest opportunity is that NSCLC is a far larger market than melanoma.

sergey with an M

 NSCLC update: 25.6% ORR, 2 CRs, 71.8% DCR, median DOR not reached at 25.4 months. Promising signal in a difficult post-checkpoint/post-chemo setting, but still only 39 patients. Biggest risk is whether these results hold as enrollment expands. Biggest opportunity is that NSCLC is a far larger market than melanoma.